Review on drug repositioning of some FDA-approved drugs for treatment of cancer/microbial diseases
RSC Advances · 2026 · 16 (35) · 33676-33689
DOI: 10.1039/d6ra03396b ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift RSC Advances, 2026. Verfasst von Magda M F Ismail und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Medicinal Chemistry and Drug Design, Faculty of Pharmacy (Girls), Al-Azhar University Cairo 11754 Egypt m.elalfy101@gmai…. Die Arbeit nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).
Abstract (Originalsprache)
Drug repurposing, also known as repositioning, is a strategic pharmaceutical method that provides a quicker and more economical substitute for de novo drug discovery by finding new therapeutic uses for licensed, unsuccessful, medications.
Autor:innen und Institutionen
- Department of Pharmaceutical Medicinal Chemistry and Drug Design, Faculty of Pharmacy (Girls), Al-Azhar University Cairo 11754 Egypt m.elalfy101@gmail.com magdaismail@azhar.edu.eg.
ORCID-Profile: Magda M F Ismail
Zitieren
APA
Ismail, M. M. F., Shawer, T. Z., ElBakry, O. M., Baumy, E. A. A., & Eissa, S. I. (2026). Review on drug repositioning of some FDA-approved drugs for treatment of cancer/microbial diseases. RSC Advances, 16(35), 33676-33689. https://doi.org/10.1039/d6ra03396b
Vancouver
Ismail MMF, Shawer TZ, ElBakry OM, Baumy EAA, Eissa SI. Review on drug repositioning of some FDA-approved drugs for treatment of cancer/microbial diseases. RSC Advances. 2026;16(35):33676-33689. doi:10.1039/d6ra03396b
BibTeX
@article{Ismail2026,
author = {Ismail, Magda M F and Shawer, Taghreed Z and ElBakry, Omneya M and Baumy, Eman A A and Eissa, Sally I},
title = {Review on drug repositioning of some FDA-approved drugs for treatment of cancer/microbial diseases},
journal = {RSC Advances},
year = {2026},
volume = {16},
number = {35},
pages = {33676--33689},
doi = {10.1039/d6ra03396b}
}
EUVIMED